Daewoong Pharmaceutical (069620.KS) is stepping up academic and marketing training for its overseas partners as it expands global sales of its botulinum toxin product Nabota.
The company said it will hold "NABOTA®EDGE: Global Academic Program" from the 3rd to the 5th at Parnas Hotel Jeju for 40 key staff from partner companies in 22 countries. The program is designed to deepen partners' understanding of the product and brand and to help them carry out consistent academic and marketing strategies in their local markets.
The event will cover Nabota's global vision and brand identity as well as its global marketing and education strategies. Training on the product and global clinical data will be paired with hands-on sessions aimed at improving product knowledge.
The program will also address academic content that partners can use in communicating with medical professionals, including basic facial anatomy for botulinum toxin procedures, Nabota's standard injection guide, and safety management and adverse event response.
Sessions have also been arranged for partners to share experiences. They include "Global Best Practices," which reviews business cases from Korea, the Asia-Pacific, the Middle East and Latin America, along with sessions and roundtables on investigator-initiated trials, the use of academic platforms and brand management.
Nabota, Daewoong's flagship botulinum toxin product, surpassed 1 trillion won in cumulative sales in 2026 and is expected to reach 300 billion won in annual revenue this year. It has won marketing approval in 69 countries across the U.S., Europe and Asia and has built partnerships in about 80 countries.
"As Nabota grows rapidly in global markets, it is important that partners in each country share a common understanding of the product and brand and build expertise," said Yoon Jun-soo, head of Daewoong Pharmaceutical's Nabota business division. "By having headquarters and global partners closely share academic and business strategies, we will strengthen the foundation for delivering Nabota's value consistently in each market."
